Drug intelligence / Profile preview

misoprostol + letrozole

Development stage
Unknown
Lead developer
Sohag University
Modality
Small Molecules
Administration
Oral, Vaginal, Sublingual
01

Overview

misoprostol + letrozole is a combination therapy investigated for the medical termination of pregnancy, particularly in the second trimester and for missed abortions. Letrozole is a third-generation non-steroidal aromatase inhibitor that blocks the conversion of androgens to estrogens. In the context of pregnancy termination, the reduction in estrogen levels is hypothesized to increase the sensitivity of the myometrium to prostaglandins and potentially interfere with progesterone synthesis, thereby facilitating the abortion process. Misoprostol is a synthetic prostaglandin E1 (PGE1) analog that binds to myometrial prostaglandin receptors, inducing cervical ripening and uterine contractions. The combination is typically administered to improve the efficacy of complete abortion and shorten the induction-to-abortion interval compared to misoprostol monotherapy.

Other names
letrozole and misoprostol
02

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER3 (Prostaglandin E2 receptor EP3 subtype)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on misoprostol + letrozole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on misoprostol + letrozole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call